Opinion|Videos|January 10, 2025
Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma
Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide an overview of the following emerging BTKi treatment regimens in treatment-naive patients with MCL.
- Acalabrutinib + bendamustine + rituximab
- Acalabrutinib + lenalidomide + rituximab
- Acalabrutinib + umbralisib + ublituximab
- Ibrutinib + rituximab
- Zanubrutinib + rituximab
Advertisement
Related to this article
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.
Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.
Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
5